Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

被引：11
|
作者：
Paz-Ares, Luis [1 ,2 ]
机构：
[1] Inst Biomed Sevilla, Seville, Spain
[2] Hosp Univ Virgen del Rocio, Seville, Spain
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 03期
关键词：
CELL LUNG-CANCER; PHASE-III TRIAL; DOCETAXEL; GEFITINIB; EGFR;
D O I：
10.1016/S1470-2045(12)70001-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225 / 227
页数：4
相关论文
共 50 条
  • [1] A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)
    Cappuzzo, F.
    Coudert, B.
    Wierzbicki, R.
    Park, K.
    Custers, F.
    Curbera, G. A.
    Giaccone, G.
    Hilbe, W.
    Klingelschmitt, G.
    Ciuleanu, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 553 - 553
  • [2] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? Reply
    Mok, Tony S. K.
    Wu, Yi-Long
    [J]. LANCET ONCOLOGY, 2013, 14 (11): : E438 - E439
  • [3] A first for first-line therapy in NSCLC
    Rebecca Kirk
    [J]. Nature Reviews Clinical Oncology, 2011, 8 (12) : 691 - 691
  • [4] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [5] ERLOTINIB MAINTENANCE THERAPY IN PATIENTS WITH STABLE DISEASE AFTER FIRST-LINE PLATINUM-DOUBLET CHEMOTHERAPY FOR ADVANCED NSCLC
    Cappuzzo, F.
    Ciuleanu, T.
    Park, K.
    Wu, Y.
    Giaccone, G.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124
  • [6] Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
    Yang, James Chih-Hsin
    Gadgeel, Shirish M.
    Sequist, Lecia VanDam
    Wu, Chien-Liang
    Papadimitrakopoulou, Vassiliki A.
    Su, Wu-Chou
    Fiore, Joseph
    Saraf, Sanatan
    Raftopoulos, Harry
    Patnaik, Amita
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : 553 - 559
  • [7] Immunotherapy Beyond First-Line in NSCLC, Still An Option
    Modrego, A.
    Bote, H.
    Jimenez-Aguilar, E.
    Ponce-Aix, S.
    Zugazagoitia, J.
    Baena, J.
    Mazarico, J. M.
    Nunez, J. A.
    Iglesias, L. C.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S354 - S355
  • [8] First-line chemotherapy for NSCLC: an overview of relevant trials
    Belani, CP
    Langer, C
    [J]. LUNG CANCER, 2002, 38 : S13 - S19
  • [9] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [10] AIH Therapy: Beyond First-Line
    Irina Adao
    Arielle Klepper
    Michele Tana
    [J]. Current Hepatology Reports, 2024, 23 (3) : 341 - 348
12345